Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

Expert Review of Hematology

Volumn 6, Issue 1, 2013, Pages 49-58

  Silver, Richard T ^a   Kiladjian, Jean Jacques ^b,c   Hasselbalch, Hans Carl ^d  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

bone marrow fibrosis; essential thrombocythemia; interferon; JAK2 mutation; myeloproliferative disorders; myeloproliferative neoplasms; Philadelphia negative neoplasms; polycythemia vera; primary myelofibrosis

Indexed keywords

'INTRON'; BCR ABL PROTEIN; JANUS KINASE 2; MULTIFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CLINICAL PRACTICE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT;

HUMANS; INTERFERONS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; RECOMBINANT PROTEINS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84873368311     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.69     Document Type: Review

References (85)

1. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22(11), 1990-1998 (2008).
2. Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Interferon-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr. Drug Targets 12(3), 392-419 (2011).
3. Hasselbalch HC. A new era for IFN-a in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev. Hematol. 4(6), 637-655 (2011).
4. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117(18), 4706-4715 (2011).
5. Chawla-Sarkar M, Lindner DJ, Liu YF et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3), 237-249 (2003). (Pubitemid 36749609)
6. Tabibzadeh S, Sun XZ, Kong QF, Kasnic G, Miller J, Satyaswaroop PG. Induction of a polarized micro-environment by human T cells and interferon-γ in three-dimensional spheroid cultures of human endometrial epithelial cells. Hum. Reprod. 8(2), 182-192 (1993). (Pubitemid 23092778)
7. Albini A, Marchisone C, Del Grosso F et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am. J. Pathol. 156(4), 1381-1393 (2000). (Pubitemid 30660014)
8. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-γ constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 87(10), 4149-4157 (1996). (Pubitemid 26152259)
9. Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-α-2b formulation. Cancer 95(2), 389-396 (2002). (Pubitemid 34787605)
10. Kuriakose E, Vandris K, Wang YL et al. Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica 97(4), 538-542 (2012).
11. Yanai Y, Sanou O, Kayano T et al. Analysis of the antiviral activities of natural IFN-a preparations and their subtype compositions. J. Interferon Cytokine Res. 21(10), 835-841 (2001). (Pubitemid 33078522)
12. Singal AK, Jampana SC, Anand BS. Peg-interferon α-2a is superior to peginterferon α-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig. Dis. Sci. 56(8), 2221-2226 (2011).
13. Michallet M, Maloisel F, Delain M et al.; PEG-Intron CML Study Group. Pegylated recombinant interferon α-2b vs recombi-nant interferon α-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A Phase III study. Leukemia 18(2), 309-315 (2004). (Pubitemid 38240047)
14. Lipton JH, Khoroshko N, Golenkov A et al.; Pegasys CML Study Group. Phase II, randomized, multicenter, comparative study of peginterferon-α-2a (40 kD) (Pegasys) versus interferon α-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia. Leuk. Lymphoma 48(3), 497-505 (2007). (Pubitemid 46487756)
15. Lu M, Zhang W, Li Y et al. Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp. Hematol. 38(6), 472-480 (2010).
16. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J. Clin. Oncol. 29(5), 573-582 (2011).
17. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 87(3), 285-293 (2012).
18. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 100(13), 4272-4290 (2002). (Pubitemid 35429665)
19. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: An alternative proposal. Blood 112(2), 231-239 (2008).
20. Cassinat B, Laguillier C, Gardin C et al.; PV-Nord Group. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia 22(2), 452-453 (2008). (Pubitemid 351250560)
21. Silver RT, Chow W, Vandris K et al. Prospective evaluation of the world health organization criteria for the diagnosis of polycythemia vera. Presented at: The 53rd Annual ASH Annual Meeting and Exposition. Abstract 3837. San Diego, CA, USA, 10-13 December 2011.
22. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: A study of patients with polycythaemia vera and apparent polycythaemia. Br. J. Haematol. 129(5), 701-705 (2005). (Pubitemid 40825832)
23. Mossuz P, Girodon F, Donnard M et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 89(10), 1194-1198 (2004).
24. Alvarez-Larrán A, Ancochea A, Angona A et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 97(11), 1704-1707 (2012).
25. Pearson TC, Guthrie DL, Simpson J et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br. J. Haematol. 89(4), 748-756 (1995).
26. Silver RT. Recombinant interferon-α for treatment of polycythaemia vera. Lancet 2(8607), 403 (1988).
27. Bellucci S, Harousseau JL, Brice P, Tobelem G. Treatment of essential thrombocythaemia by α 2a interferon. Lancet 2(8617), 960-961 (1988).
28. Linkesch W, Gisslinger H, Ludwig H, Flener R, Sinzinger H. [Therapy with interferon (recombinant IFN-α-2C) in myeloproliferative diseases with severe thrombocytoses]. Acta Med. Austriaca 12(5), 123-127 (1985). (Pubitemid 16128362)
29. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer 107(3), 451-458 (2006). (Pubitemid 44107203)
30. Larsen TS, Møller MB, de Stricker K et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with α-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 14(6), 331-334 (2009).
31. Silver RT, Vandris K. Recombinant interferon α (rIFN α-2b) may retard progression of early primary myelofibrosis. Leukemia 23(7), 1366-1369 (2009).
32. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-a may retard progression of early primary myelofibrosis: A preliminary report. Blood 117(24), 6669-6672 (2011).
33. Kiladjian JJ, Cassinat B, Turlure P et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood 108(6), 2037-2040 (2006). (Pubitemid 44395018)
34. Di Nisio M, Barbui T, Di Gennaro L et al.; European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br. J. Haematol. 136(2), 249-259 (2007).
35. Turlure P, Cambier N, Roussel M et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon {α}-2a (peg-IFN{α}-2a) therapy in polycythemia vera (PV): long term results of a Phase 2 trial. Blood (ASH Annual Abstracts) 118(21), 280 (2011).
36. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin. Hematol. 23(2), 132-143 (1986).
37. Marchioli R, Finazzi G, Specchia G et al. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl. J. Med. 368, 22-23 (2013).
38. Berlin NI. Treatment of the myeloproliferative disorders with 32P. Eur. J. Haematol. 65(1), 1-7 (2000).
39. Berk PD, Goldberg JD, Silverstein MN et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N. Engl. J. Med. 304(8), 441-447 (1981). (Pubitemid 11178999)
40. Najean Y, Rain JD. The very long-term evolution of polycythemia vera: An analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin. Hematol. 34(1), 6-16 (1997). (Pubitemid 27063137)
41. Fretham SJ, Carlson ES, Georgieff MK. The role of iron in learning and memory. Adv. Nutr. 2(2), 112-121 (2011).
42. Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur. J. Heart Fail. 14(4), 423-429 (2012).
43. Balci K, Utku U, Asil T, Büyükkoyuncu N. Deep cerebral vein thrombosis associated with iron deficiency anaemia in adults. J. Clin. Neurosci. 14(2), 181-184 (2007). (Pubitemid 44855620)
44. Spivak JL. An inconvenient truth. Blood 115(14), 2727-2728 (2010).
45. Spivak JL, Hasselbalch H. Hydroxycarbamide: A user's guide for chronic myeloproliferative disorders. Expert Rev. Anticancer Ther. 11(3), 403-414 (2011).
46. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J. Clin. Oncol. 29(29), 3907-3913 (2011).
47. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence of allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia 22(7), 1299-1307 (2008).
48. Tefferi A. Mutational analysis in BCRABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. Leuk. Lymphoma 51(4), 576-582 (2010).
49. Silver RT, Vandris K, Wang YL et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk. Res. 35(2), 177-182 (2011).
50. Quintás-Cardama A, Kantarjian H, Manshouri T et al. Pegylated interferon α-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J. Clin. Oncol. 27(32), 5418-5424 (2009).
51. Kiladjian JJ, Cassinat B, Chevret S et al. Pegylated interferon-α- 2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8), 3065-3072 (2008).
52. Jones AV, Silver RT, Waghorn K et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107(8), 3339-3341 (2006).
53. Samuelsson J, Mutschler M, Birgegård G, Gram-Hansen P, Björkholm M, Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon α-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 91(9), 1281-1282 (2006). (Pubitemid 44408447)
54. Kiladjian JJ, Massé A, Cassinat B et al.; French Intergroup of Myeloproliferative Neoplasms (FIM). Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 24(8), 1519-1523 (2010).
55. Barbui T, Finazzi G, Carobbio A et al. Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). Blood 120(26), 5128-5133 (2012).
56. Girodon F, Dutrillaux F, Broséus J et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: A population-based study of 311 patients. Leukemia 24(4), 900-903 (2010).
57. Campbell PJ, Bareford D, Erber WN et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J. Clin. Oncol. 27(18), 2991-2999 (2009).
58. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin. Proc. 81(2), 159-166 (2006). (Pubitemid 43205767)
59. Passamonti F, Rumi E, Arcaini L et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: A study of 605 patients. Haematologica 93(11), 1645-1651 (2008).
60. Radaelli F, Colombi M, Calori R et al. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol. Oncol. 25(3), 115-120 (2007). (Pubitemid 47507878)
61. Johansson P, Mesa R, Scherber R et al. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk. Lymphoma 53(3), 441-444 (2012).
62. Roy L, Ianotto JC, Guilhot J et al. Pegylated interferon α-2a therapy for patients with high risk essential thrombocythemia: A retrospective analysis on 59 patients. on behalf of the French Intergroup of Myeloproliferative Disorders (FIM). Blood 116(21), a1974 (2010).
63. Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: Actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br. J. Haematol. 118(3), 786-790 (2002). (Pubitemid 35007383)
64. Barbui T, Thiele J, Passamonti F et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J. Clin. Oncol. 29(23), 3179-3184 (2011).
65. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-α in the treatment of essential thrombocythemia. Leuk. Lymphoma 22(Suppl. 1), 135-142 (1996).
66. Hasselbalch HC. Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment? Leuk. Res. 33(1), 11-18 (2009).
67. Hasselbalch HC, Kiladjian JJ, Silver RT. Interferon α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J. Clin. Oncol. 29(18), e564-e565 (2011).
68. Ianotto JC, Kiladjian JJ, Demory JL et al. PEG-IFN-α-2a therapy in patients with myelofibrosis: A study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myé loprolifératifs (FIM). Br. J. Haematol. 146(2), 223-225 (2009).
69. Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica 90(11), 1477-1483 (2005). (Pubitemid 41658760)
70. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br. J. Haematol. 129(3), 293-306 (2005). (Pubitemid 40646888)
71. Passamonti F, Randi ML, Rumi E et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2(617V>F) mutation. Blood 110(2), 485-489 (2007). (Pubitemid 47105385)
72. Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN. The management and outcome of four pregnancies in women with idiopathic myelofibrosis. Br. J. Haematol. 142(3), 480-482 (2008). (Pubitemid 351962173)
73. Vantroyen B, Vanstraelen D. Management of essential thrombocythemia during pregnancy with aspirin, interferon α-2a and no treatment. A comparative analysis of the literature. Acta Haematol. 107(3), 158-169 (2002). (Pubitemid 34455080)
74. Elliott MA, Tefferi A. Thrombocythaemia and pregnancy. Best Pract. Res. Clin. Haematol. 16(2), 227-242 (2003).
75. Melillo L, Tieghi A, Candoni A et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. Am. J. Hematol. 84(10), 636-640 (2009).
76. Aliverti V, Bonanomi L, Giavini E. Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats. Arch. Toxicol. Suppl. 4, 239-247 (1980). (Pubitemid 11227829)
77. Rumi E, Harutyunyan A, Elena C et al. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am. J. Hematol. 86(12), 974-979 (2011).
78. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119(14), 3219-3225 (2012).
79. Barbui T, Thiele J, Passamonti F et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 119(10), 2239-2241 (2012).
80. Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sørensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study. Blood 118(25), 3219-3225 (2012).
81. Samuelsson J, Hasselbalch H, Bruserud O et al.; Nordic Study Group for Myeloproliferative Disorders. A Phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106(11), 2397-2405 (2006). (Pubitemid 43787664)
82. Gowin K, Thapaliya P, Samuelson J et al. Experience with pegylated interferon a-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 97(10), 1570-1573 (2012).
83. Finazzi G. How to manage essential thrombocythemia. Leukemia 26(5), 875-882 (2012).
84. Beer PA, Erber WN, Campbell PJ, Green AR. How I treat essential thrombocythemia. Blood 117(5), 1472-1482 (2011).
85. Bracarda S, Eggermont AM, Samuelsson J. Redefining the role of interferon in the treatment of malignant diseases. Eur. J. Cancer 46(2), 284-297 (2010).